1. P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY. (23rd June 2022) Authors: Herrera, A. F.; Lavie, D.; Johnson, N. A.; Avigdor, A.; Borchmann, P.; Andreadis, C.; Bazargan, A.; Gregory, G.; Keane, C.; Inna, T.; Vucinic, V.; Zinzani, P. L.; Zhang, H.; Pillai, P.; Marinello, P.; Timmerman, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 977 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗